Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – What’s Next?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) shares saw an uptick in trading volume on Thursday . 6,139 shares traded hands during trading, a decline of 27% from the previous session’s volume of 8,428 shares.The stock last traded at $17.69 and had previously closed at $17.15.

Analyst Ratings Changes

A number of analysts recently commented on PHAR shares. Weiss Ratings cut shares of Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, November 7th. Zacks Research upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $30.00.

Pharming Group Stock Performance

The firm has a market cap of $1.18 billion, a PE ratio of -1,748.25 and a beta of 0.03. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The firm’s 50 day moving average price is $14.45 and its two-hundred day moving average price is $12.21.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.05. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The company had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group has set its FY 2025 guidance at EPS. On average, research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,979 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.